<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR22">
 <label>22.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Younes</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Bartlett</surname>
    <given-names>NL</given-names>
   </name>
   <name>
    <surname>Leonard</surname>
    <given-names>JP</given-names>
   </name>
   <name>
    <surname>Kennedy</surname>
    <given-names>DA</given-names>
   </name>
   <name>
    <surname>Lynch</surname>
    <given-names>CM</given-names>
   </name>
   <name>
    <surname>Sievers</surname>
    <given-names>EL</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas</article-title>
  <source>N Engl J Med</source>
  <year>2010</year>
  <volume>363</volume>
  <fpage>1812</fpage>
  <lpage>1821</lpage>
  <pub-id pub-id-type="doi">10.1056/NEJMoa1002965</pub-id>
  <?supplied-pmid 21047225?>
  <pub-id pub-id-type="pmid">21047225</pub-id>
 </element-citation>
</ref>
